معرفی
Melissa Barker-Haliski is an Associate Professor at the University of Washington School of Pharmacy, affiliated with the Department of Pharmaceutics, Plein Center for Aging Faculty, and School Faculty. She actively collaborates with UW faculty in the School of Medicine to develop novel preclinical platforms for antiseizure drug discovery.
- Education: BA in Biology/French (University of Oregon), PhD in Pharmacology/Toxicology (University of Utah)
Her research focuses on preclinical drug development for epilepsy in special populations, particularly pharmacoresistant epilepsy and aging-related neurological disorders. She investigates seizure susceptibility and pharmacotherapeutic response in aged patients, aiming to bridge basic science and clinical application through translational research.
Recent publications highlight her work on translational concordance frameworks (PAC-FOS), pharmacologic excipient toxicity studies, genotype-influenced seizure outcomes in Alzheimer’s models, and molecular target discovery in temporal lobe epilepsy. These studies emphasize preclinical model validation and antiseizure efficacy.
She leads the Barker-Haliski Laboratory, which develops innovative preclinical platforms to evaluate investigational therapies, understand molecular/genetic mechanisms of seizures, and identify biomarkers for drug screening. The lab trains graduate (Pharmaceutics, Neuroscience) and undergraduate students in epilepsy research.
